Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Analyst
Jessica Tassan
Period: Reporting periods mapped to calendar 2025 Q1 – 2025 Q4 (4 quarters; questions recorded in 3).
- Questions
- 3on tracked calls
- Challenge rate
- 0%none of 3 questionsLimited sample
- Companies
- 1questioned at least once
- Reporting periods
- 3with questions
These figures cover the whole profile: every tracked question, all reporting periods.
How to read these numbers
Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right.
Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.
No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.
Fewer than 3 questions. A company-level rate is withheld when fewer than 3 questions were recorded for that company; the questions are still counted everywhere else.
Small samples. Profiles with fewer than 10 questions are marked Limited sample.
Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.
Questions asked
Grouped by company, most questions first. Open a company to read its questions, newest reporting period first.
Showing 3 of 3 questions from 1 company
UNHUnitedHealth Group Incorporated3 questions · 3 reporting periods · 0 of 3 challenging
Calendar 2025 Q4
what would you highlight for investors from the independent reviews of UNH business practices that you all published in December?
Show response
Hemsley said independent reviews were actually very positive and focused on overall environments, controls, oversight and governance for risk assessment practices. Following up with independent review of risk accuracy.
Calendar 2025 Q2
can you help us understand the split and timing between kind of MLR improvement and then incremental operating leverage
Show response
Hunter described margin recovery from product design optimization, care management investment, meaningful benefit adjustments, and operational cost efficiency. AI use cases driving efficiency and informing forecasts. Partnership with Sandeep and Optum team on AI capabilities supportive of 2027 and beyond targets at midpoint or above of 2-4% range.
Calendar 2025 Q1
just wondering if you all can elaborate on UHC's dominance in the C-SNP market?
Show response
Hunter confirmed on track for 800,000 MA growth target. AEP momentum carried into OEP with notably strong retention. Diversified growth across community HMO, full dual, and chronic condition plans. Value-based care integration with internal and external providers positions well for managing chronic complex members.
Challenge rate by company
Every company this analyst questioned, most questions first. A company-level rate is shown from 3 questions; below that it is withheld.
| Company | Questions | Challenge rate |
|---|---|---|
| UNH UnitedHealth Group Incorporated | 3 | 0%none of 3 questions |
- UNHUnitedHealth Group Incorporated · 3 questions0%none of 3 questions
Activity by reporting period
Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.
| Calendar period | Questions | Challenge rate | Companies |
|---|---|---|---|
| 2025 Q1 | 1 | 0%none of 1 question | 1 |
| 2025 Q2 | 1 | 0%none of 1 question | 1 |
| 2025 Q3 | No questions recorded | — | — |
| 2025 Q4 | 1 | 0%none of 1 question | 1 |
- 2025 Q11 question · challenge rate 0% (none of 1 question) · 1 company
- 2025 Q21 question · challenge rate 0% (none of 1 question) · 1 company
- 2025 Q3No questions recorded
- 2025 Q41 question · challenge rate 0% (none of 1 question) · 1 company
Topics
Topics tagged on this analyst’s questions.
- Regulation Policy1
- Guidance Reliability1
- Margin1
- Innovation & R&D1
- Demand1
- Competitive Dynamics1